Addressing Europe’s plasma deficit
Market Access
Across the European Union approximately 300,000 patients with chronic conditions, such as haemophilia and severe immune-deficiency, depend on plasma-derived medicines, which can only be manufactured using donated blood plasma as there is no way to synthesise the raw material. However, with an estimated shortage of 5 million litres of plasma needed to manufacture these products, how can companies and regulators work to address the shortfall?
In this issue, pharmaphorum editor-in-chief Jonah Comstock sat down (virtually) with Takeda Pharmaceuticals’, Giles Platford, to find out.
Check out the full interview to learn more:
• Read the full article in pharmaphorum's Deep Dive digital magazine
